English

Allotment og Share Options

Report this content

Oslo, September 5th 2011: According to the resolution by the Annual General Meeting on 23 May 2011, the Board of Directors in DiaGenic ASA today allotted options to DiaGenic employees. The share options have strike price of NOK 6.00 per share, which is set based on last week weighted share price + 10%. The options have life of 4 years and can be exercised after 3 years.

The following primary insiders have today been allotted options:

  • Erik Christensen, CEO: 120,000 options
  • Magnus Sjøgren, Medical Director: 40,000 options
  • Morten Sten Johansen, International Business Director: 40,000 options
  • Edith Rian, Director Operations: 40,000 options
  • Ruben Ekbråten, Finance Director: 40,000 options
  • Anders Lönneborg, Research Director: 16,000 options
  • Praveen Sharma, Head of IP : 16,000 options
  • Gisle Grave, Clinical R&D Director: 16,000 options
  • Torbjørn Lindahl, Bioinformatics Manager: 16,000 options
  • Line Røed, Senior Scientist: 16,000 options

Today a total of 432,000 options have been allotted, including allotments listed above. After the allotment today, DiaGenic have a total of 432,000 options outstanding.

Contact:

Erik Christensen, CEO

Telephone: 47 95939918

e-mail: erik.christensen@diagenic.com

About DiaGenic ASA

DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts of the body. DiaGenic has developed and CE marked two blood based diagnostic tests, BCtect® for early breast cancer detection and ADtect® for early detection of Alzheimer’s Disease. The company protects its technology through an extensive patent portfolio. DiaGenic promotes its products towards leading pharmaceutical and imaging companies, and towards clinicians. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com

Subscribe